Talquetamab in Elderly Patients
A Phase 2 Single-Arm Study of Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 23 patients (estimated)
- Sponsors
- Icahn School of Medicine at Mount Sinai
- Collaborators
- Johnson & Johnson
- Tags
- Bispecific Antibody, CD3, GPRC5D
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2061
- NCT Identifier
- NCT06827860
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.